{"schema_version":"secwatch.filing_event.v1","accession":"0001438133-25-000237","form_type":"8-K","ticker":"TNDM","cik":"0001438133","company_name":"TANDEM DIABETES CARE INC","filed_at":"2025-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.417280+00:00","generated_at":"2026-05-16T11:58:00.283848+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Tandem Diabetes amends bylaws with updated advance notice, proxy card, voting rules","bullets":["Board adopted Amended and Restated Bylaws on Dec 26, 2025 as part of periodic governance review.","Advance notice provisions updated: stockholder nominees must satisfy Rule 14a-19 requirements; non-compliant nominees disregarded.","White proxy card reserved exclusively for Board; other solicitations must use non-white cards.","Voting standard (plurality for contested, majority for uncontested) determined 10 days before notice mailing.","Board given express authority to cancel, reschedule, or postpone stockholder meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0001438133-25-000237","json":"https://secwatch.observer/filing/0001438133-25-000237.json","markdown":"https://secwatch.observer/filing/0001438133-25-000237.md","text":"https://secwatch.observer/filing/0001438133-25-000237.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/0001438133-25-000237-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/tndm-20251226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:58:00.283848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ddd2f89e6ccba8f45cf653070764f3524c969296","claim":"TANDEM DIABETES CARE INC: Amended and Restated Bylaws effective December 26, 2025, updating advance notice provisions, meeting cancellation authority, proxy card color rule, indemnification, notice provisions, voting standards, stockholder list requirement, and certain technical changes (effective 2025-12-26).","evidence_excerpt":"On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/0001438133-25-000237-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-251689","ticker":"SCHW","company_name":"SCHWAB CHARLES CORP","filed_at":"2026-06-01T21:00:25+00:00","headline":"Charles Schwab files Certificate of Elimination for Series I Preferred Stock","event_type":"other","sec_items":["5.03","9.01"],"materiality_score":0.15,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251689","json":"https://secwatch.observer/filing/0001193125-26-251689.json","markdown":"https://secwatch.observer/filing/0001193125-26-251689.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/316709/000119312526251689/0001193125-26-251689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/316709/000119312526251689/d143555d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/0001438133-25-000237-index.htm","comparable_excerpt":"On June 1, 2026, The Charles Schwab Corporation (the “Company”) filed a Certificate of Elimination with the Secretary of State of the State of Delaware with respect to the Company’s 4.000% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series I (“Series I Preferred Stock”), which, effective upon filing, eliminated from the Company’s Fifth Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations for the Series I Preferred Stock.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/316709/000119312526251689/0001193125-26-251689-index.htm"}},{"accession":"0001395942-26-000022","ticker":"OPLN","company_name":"OPENLANE, Inc.","filed_at":"2026-05-29T17:57:10+00:00","headline":"OPENLANE eliminates Series A Convertible Preferred Stock from charter","event_type":"other","sec_items":["5.03","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001395942-26-000022","json":"https://secwatch.observer/filing/0001395942-26-000022.json","markdown":"https://secwatch.observer/filing/0001395942-26-000022.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395942/000139594226000022/0001395942-26-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395942/000139594226000022/kar-20260529.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/0001438133-25-000237-index.htm","comparable_excerpt":"On May 29, 2026, OPENLANE, Inc. (the “Company”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware effecting the elimination of the Certificate of Designations relating to the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”) previously filed by the Company with the Secretary of State of the State of Delaware on June 9, 2020.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1395942/000139594226000022/0001395942-26-000022-index.htm"}},{"accession":"0001213900-26-062184","ticker":"RLMD","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2026-05-28T20:59:47+00:00","headline":"Relmada increases authorized common shares to 200M; stockholders approve 2021 Plan amendment","event_type":"other","sec_items":["5.03","5.07","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062184","json":"https://secwatch.observer/filing/0001213900-26-062184.json","markdown":"https://secwatch.observer/filing/0001213900-26-062184.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/0001213900-26-062184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/ea0292521-8k_relmada.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/0001438133-25-000237-index.htm","comparable_excerpt":"On May 28, 2026, Relmada Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 200,000,000 shares (the “ Charter Amendment ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/0001213900-26-062184-index.htm"}},{"accession":"0001551306-26-000109","ticker":"PGNY","company_name":"Progyny, Inc.","filed_at":"2026-05-27T13:13:46+00:00","headline":"Progyny shareholders approve elimination of supermajority voting requirements","event_type":"other","sec_items":["5.03","5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001551306-26-000109","json":"https://secwatch.observer/filing/0001551306-26-000109.json","markdown":"https://secwatch.observer/filing/0001551306-26-000109.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551306/000155130626000109/0001551306-26-000109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551306/000155130626000109/pgny-20260521.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/0001438133-25-000237-index.htm","comparable_excerpt":"Progyny, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026. At the Annual Meeting, the Company’s stockholders approved certain amendments (the “Charter Amendments”) to the Company’s Certificate of Incorporation. As further described in Proposals 4 and 5 of the Company’s definitive proxy statement filed on April 10, 2026 (the “Proxy Statement”), the Charter Amendments (a) eliminate certain supermajority voting requirements (the “Supermajority Amendments”), and (b) eliminate the default supermajority voting requirement concerning certain business combinations. The Charter Amendments became effective upon the filing of a Certificate of Amendment (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware on May 21, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1551306/000155130626000109/0001551306-26-000109-index.htm"}},{"accession":"0000089089-26-000046","ticker":"SCI","company_name":"SERVICE CORP INTERNATIONAL","filed_at":"2026-05-08T23:59:59+00:00","headline":"SCI shareholders approve board governance changes: director minimum cut to 3, board can fill vacancies","event_type":"other","sec_items":["5.03","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000089089-26-000046","json":"https://secwatch.observer/filing/0000089089-26-000046.json","markdown":"https://secwatch.observer/filing/0000089089-26-000046.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/89089/000008908926000046/0000089089-26-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/89089/000008908926000046/sci-20260506.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/0001438133-25-000237-index.htm","comparable_excerpt":"The amendments to the Articles of Incorporation, which became effective on May 7, 2026, and the amendments to the Bylaws, which became effective on May 6, 2026 , include (i) changes permitting the Board to increase the number of directors and fill newly created vacancies, thereby eliminating restrictions requiring that newly created directorships be filled only by shareholders at an annual or special meeting, and (ii) changes reducing the minimum number of directors constituting the Board from nine to three directors (with the maximum remaining at fifteen directors).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/89089/000008908926000046/0000089089-26-000046-index.htm"}},{"accession":"0001767042-26-000037","ticker":"KGS","company_name":"Kodiak Gas Services, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Kodiak shareholders approve board declassification and supermajority removal","event_type":"other","sec_items":["5.03","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001767042-26-000037","json":"https://secwatch.observer/filing/0001767042-26-000037.json","markdown":"https://secwatch.observer/filing/0001767042-26-000037.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1767042/000176704226000037/0001767042-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1767042/000176704226000037/kgs-20260507.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/0001438133-25-000237-index.htm","comparable_excerpt":"At the 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of Kodiak Gas Services, Inc. (the “Company”) held on May 7, 2026, the Company’s shareholders approved certain amendments (the “Charter Amendments”) to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to (i) phase in declassification of the Board of Directors (the “Board”) and (ii) eliminate certain supermajority voting requirements and other obsolete provisions.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1767042/000176704226000037/0001767042-26-000037-index.htm"}},{"accession":"0001654954-26-004356","ticker":"DAIO","company_name":"DATA I/O CORP","filed_at":"2026-05-05T23:59:59+00:00","headline":"Data I/O moves 2026 annual meeting to July 8; removes May meeting requirement","event_type":"other","sec_items":["5.03","8.01","9.01"],"materiality_score":0.15,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-004356","json":"https://secwatch.observer/filing/0001654954-26-004356.json","markdown":"https://secwatch.observer/filing/0001654954-26-004356.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/351998/000165495426004356/0001654954-26-004356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/351998/000165495426004356/daio_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/0001438133-25-000237-index.htm","comparable_excerpt":"On April 29, 2026, the Board of Directors (the “Board”) of Data I/O Corporation (the “Company”) adopted an amendment to the Bylaws of the Company (the “Bylaw Amendment”) which became effective immediately. The Bylaw Amendment modifies Article II Section (2) of the Company’s Bylaws to eliminate the requirement that the annual meeting of shareholders be held during the month of May.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/351998/000165495426004356/0001654954-26-004356-index.htm"}},{"accession":"0001178253-26-000017","ticker":"SCYX","company_name":"SCYNEXIS INC","filed_at":"2026-05-29T20:01:37+00:00","headline":"SCYNEXIS effects 1:8 reverse stock split; authorized shares cut to 18.75M","event_type":"other","sec_items":["5.03","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001178253-26-000017","json":"https://secwatch.observer/filing/0001178253-26-000017.json","markdown":"https://secwatch.observer/filing/0001178253-26-000017.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000117825326000017/0001178253-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000117825326000017/scyx-20260528.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000237/0001438133-25-000237-index.htm","comparable_excerpt":"On May 28, 2026, SCYNEXIS, Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”), to effect a one-for-eight (1:8) reverse stock split of its outstanding common stock (the “Reverse Stock Split”) and a reduction in the total number of authorized shares of its common stock from 150,000,000 to 18,750,000, effective as of May 29, 2026 (the “Share Reduction”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1178253/000117825326000017/0001178253-26-000017-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}